This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Amyloidosis
E4_AMYLOIDOSIS
amyloidosis: A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.
Endpoint definition
↥
FinnGen phenotype data
392423 individuals
Apply sex-specific rule None
392423
Check conditions None
392423
Check pre-conditions, main-only, mode, registry filters
2 out of 7 registries used, show all original rules.
499
Check minimum number of events None
499
Include endpoints
510
Remove individuals based on genotype QC
500
E4_AMYLOIDOSIS
Control definitions
Control exclude
E4_METABOLIA
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
E70-E90
Name in latin
Amyloidosis
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Amyloidosis
based on the number of shared cases.
Broader endpoints:
- Metabolic disorders
- Rheumatoid arthritis-related co-morbidities
- Endocrine, nutritional and metabolic diseases
- Endocrine, nutritional and metabolic diseases
- Rheumatological diseases related comorbidities
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 500 | 244 | 256 |
| Unadjusted prevalence (%) | 0.13 | 0.12 | 0.15 |
| Mean age at first event (years) | 62.60 | 58.59 | 66.42 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: E4_AMYLOIDOSIS – Amyloidosis
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Amyloidosis
↥Endpoint not on priority list, no data to show.